Compugen announced that the first patient has been dosed in the triple combination proof-of-concept study evaluating COM701, Compugen’s potential first-in-class anti-PVRIG antibody, in combination with COM902, Compugen’s potential best-in-class anti-TIGIT antibody and pembrolizumab in patients with metastatic microsatellite stable colorectal cancer. Initial findings expected by the end of 2023.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on CGEN: